Providence Therapeutics

What Providence Therapeutics does

Providence Therapeutics is a clinical-stage Canadian mRNA biotechnology company founded in 2015 in Calgary, Alberta by Brad Sorenson after his son's glioblastoma diagnosis, with additional operations in Toronto. The company operates an integrated mRNA "ecosystem" consisting of three platform pillars: an mRNA Medicines Platform (proprietary sequence design and manufacturing), the INTENT™ LNP delivery platform (portfolio of ionizable lipids for targeted payload delivery, including the dendritic/macrophage-targeting INTENT-3 reagent), and a validated Manufacturing Platform capable of producing personalized vaccines through pandemic-scale quantities. The pipeline spans oncology precision candidates (PTX-102, PTX-103, PTX-106, PTX-108, the latter targeting pediatric brain tumors), infectious disease vaccines (PTX-202 rabies, PTX-203 shingles, PTX-204 malaria, PTX-205 influenza, PTX-206 salmonella), and animal health (PTX-301), built on top of the clinically validated PTX-COVID19-B backbone which showed non-inferiority to Pfizer/BioNTech's Comirnaty in a 565-participant Phase 2 trial.

The company generates revenue almost exclusively through licensing, milestone, and grant arrangements rather than product sales. Its largest single deal was a $100M upfront partnership with Everest Medicines in September 2021 covering mRNA COVID-19 vaccine rights in Greater China, Southeast Asia, and Pakistan plus a 50/50 global collaboration on two additional indications — an arrangement terminated in 2024 amid waning vaccine demand. Other revenue sources have included a $2.118M Bill & Melinda Gates Foundation grant (Dec 2021) for low- and middle-income country access, a $15M+ multi-year supply and GMP manufacturing agreement with Northern RNA (Sep 2021), and a term sheet with Biological E. for India-based mRNA manufacturing. Distribution channels are partner-mediated across Asia-Pacific, Canada, and select WHO Solidarity Trial geographies (Philippines, Mali, Colombia), with academic and government partners providing clinical trial infrastructure. The company is currently pursuing $80M in institutional funding to achieve commercial self-sustainability and has refocused on its oncology roots, anchored by the February 2026 launch of the world-first PaedNEO-VAX pediatric personalized mRNA cancer vaccine trial in Australia.

Name

Providence Therapeutics

Legal name

Providence Therapeutics Holdings Inc.

Website

https://providencetherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Providence Therapeutics is a clinical-stage Canadian mRNA biotechnology company developing personalized cancer vaccines and infectious disease vaccines using its proprietary mRNA platform, INTENT™ LNP delivery technology, and validated manufacturing capabilities, serving oncology patients and global health partners.

Ownership category

akta.pro rank

Product category

mRNA Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)

Keywords

• MRNA therapeutics
• Cancer vaccines
• Lipid nanoparticles
• Infectious disease vaccines
• Biotechnology platform

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Licensing and Milestone Payments: Providence licenses its mRNA vaccine technology to pharmaceutical partners like Everest Medicines, receiving upfront payments ($100M from Everest), milestone payments based on development achievements, profit sharing, and royalties on sales.
2. Technology Platform Licensing: Full technology transfer of manufacturing processes to partners with associated licensing fees and ongoing collaboration revenues from co-development agreements.
3. Foundation and Government Grants: Funding from organizations like the Bill & Melinda Gates Foundation ($2.118M USD) for process development and validation activities supporting vaccine access in low-and middle-income countries.
4. Partnership Funding: Seeking $80 million in institutional funding to become commercially self-sustaining. Partnership with Australian Government and philanthropic donors for pediatric mRNA cancer vaccine trial.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels9 records

Core offering

Providence Therapeutics is a clinical-stage mRNA biotechnology company that develops personalized mRNA cancer vaccines and prophylactic infectious disease vaccines using its proprietary mRNA Medicines Platform combined with the INTENT™ lipid nanoparticle (LNP) delivery system. The company offers an integrated end-to-end mRNA ecosystem spanning antigen design, LNP formulation, and GMP manufacturing for partners and collaborators. Its pipeline includes oncology candidates (PTX-102, PTX-103, PTX-106, PTX-108), infectious disease vaccines (PTX-COVID19-B, PTX-COVID19-M1.2, PTX-202 rabies, PTX-203 shingles, PTX-204 malaria, PTX-205 influenza, PTX-206 salmonella), and one animal health program (PTX-301).

Product overview

Providence Therapeutics is a clinical-stage mRNA biotechnology company with a platform-based approach consisting of three core technology pillars: the mRNA Medicines Platform (proprietary mRNA design and manufacturing), the INTENT™ LNP Platform (next-generation lipid nanoparticle delivery), and a validated Manufacturing Platform (GMP production capabilities). The company operates programs across three therapeutic areas: Oncology (PTX-102, PTX-103, PTX-106, PTX-108), Infectious Diseases (PTX-202/Rabies, PTX-203/Shingles, PTX-204/Malaria, PTX-205/Influenza, PTX-206/Salmonella, and COVID-19 vaccines PTX-COVID19-B and PTX-COVID19-M1.2), and Animal Health (PTX-301). The platforms work together: the mRNA Medicines Platform designs the therapeutic sequences, INTENT™ LNP Platform enables targeted delivery, and the Manufacturing Platform produces clinical and commercial-scale quantities.

Differentiator

Problem solved

Functional benefit

Products and services

• PTX-COVID19-B mRNA COVID-19 vaccine candidate encoding the spike protein of SARS-CoV-2 in a lipid nanoparticle formulation. Demonstrated non-inferiority to Comirnaty (Pfizer/BioNTech) in a Phase 2 study of 565 participants and was included in the WHO Solidarity Trial Vaccines program.
• PTX-COVID19-M1.2 (Bivalent) Bivalent mRNA COVID-19 vaccine encoding spike proteins from Wuhan-Hu-1 and Omicron BA.2.12.1 variants, designed to elicit broad immune responses against multiple Omicron subvariants.
• Tri-antigenic COVID-19 Vaccine Next-generation COVID-19 vaccine containing mRNA encoding spike, nucleocapsid (N), and membrane (M) proteins. Targets conserved proteins to provide broad protection against multiple strains.
• PTX-102 Precision medicine oncology candidate for solid tumors using precision antigens.
• PTX-103 Precision medicine oncology candidate targeting glioblastoma using common antigens.
• PTX-106 Personalized cancer vaccine program tailored to individual patient tumor biology.
• PTX-108 Pediatric brain cancer vaccine program for personalized medicine approach.
• PTX-202 (Rabies Vaccine) Post-exposure prophylaxis rabies vaccine using mRNA technology. Achieved preclinical proof-of-concept showing higher neutralizing antibodies and T-cell response than a commercial inactivated comparator vaccine.
• PTX-203 (Shingles) Prophylactic vaccine candidate for shingles using mRNA technology.
• PTX-204 (Malaria) Multi-antigen prophylactic malaria vaccine using mRNA technology.
• PTX-205 (Influenza) Highly pathogenic influenza prophylactic vaccine using mRNA technology.
• PTX-206 (Salmonella) Multi-antigen prophylactic Salmonella vaccine using mRNA technology.
• PTX-301 Highly pathogenic influenza prophylactic vaccine for animal health applications.
• mRNA Medicines Platform Providence's mRNA Medicines Platform is an agile, robust, clinically proven platform providing proprietary mRNA design algorithms and sequence engineering capabilities for the rapid development of mRNA-based therapeutics, both internally and for partners and collaborators. Licensed and used in co-development agreements with Everest Medicines and Biological E.
• INTENT™ LNP Platform Next-generation lipid nanoparticle (LNP) delivery platform developed by Providence with a portfolio of rationally designed ionizable lipids for optimized delivery of nucleic acids. Features include transfection efficiency, low toxicity, and target specificity for in vitro and in vivo payload delivery. Licensed to partners including Everest Medicines.
• Manufacturing Platform Validated GMP manufacturing platform with regulatory capabilities capable of producing drugs from personalized cancer vaccine scale up to pandemic-scale quantities. Full technology transfer capabilities delivered to partners including Biological E and Southern RNA.

Quantifiable outcome

• PTX-COVID19-B demonstrated non-inferior neutralizing antibody GMT ratio (0.84, 95% CI 0.69-1.02) compared to Comirnaty in Phase 2 study
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core, flagship and minor.

• Southern RNAcoreTechnology or Integration · 4 February 2026Australian manufacturing partner for production of customized mRNA vaccines in the PaedNEO-VAX trial with expected turnaround of approximately 10 weeks from enrollment to dosing.
• Ontario Institute for Cancer Research (OICR)coreStrategic or Co-development Partner · 23 May 2024Collaboration combining OICR's cancer genomics and translational drug discovery expertise with Providence's next-generation mRNA and LNP technology to accelerate preclinical drug development. Guaranteed country-of-origin rights to Canada for all programs.
• University Health Network (UHN)coreStrategic or Co-development Partner · 2 June 2023mRNA drug discovery partnership for developing mRNA-based vaccines and therapeutics for difficult to treat cancers and infectious diseases. Unique arrangement provides country-of-origin rights to Canada for all therapies developed. Product development and manufacturing to be done in Canada.
• The Hospital for Sick Children (SickKids)coreTechnology or Integration · 12 July 2022Exclusive licensing agreement for immunotargeting technology platform that provides innovative approach to generating adjuvant-free vaccines by targeting Antigen Presenting Cells via MHC Class II molecules.
• WHO Solidarity Trial Vaccines ProgramflagshipStrategic or Co-development Partner · 20 December 2021PTX-COVID19-B approved for inclusion in WHO international randomized clinical trial to rapidly evaluate efficacy and safety of promising new candidate vaccines. Trial sites in Philippines, Mali, and Colombia.
• Northern RNAcoreTechnology or Integration · 14 September 2021Multi-year agreement valued at over $15 million for Northern RNA to provide Plasmid DNA, mRNA Cap Analogs and GMP certified manufacturing to support Providence's COVID-19 mRNA vaccine development and manufacturing requirements.
• Everest MedicinesflagshipStrategic or Co-development Partner · 13 September 2021Comprehensive agreements for licensing mRNA COVID-19 vaccine in emerging markets in Asia (Greater China, Southeast Asia, Pakistan) with $100M upfront payment, up to $300M in milestone payments, profit sharing, and royalties. Additionally, 50/50 worldwide collaboration for developing products in two additional indications with full technology transfer.
• Biological E. LimitedcoreStrategic or Co-development Partner · 1 June 2021Term sheet for licensing and collaboration of mRNA vaccine with Biological E to run pivotal trial in India and seek emergency use authorization. Target of 600 million dose production capacity in 2022 with goal of 1 billion doses. Providence to export 30 million doses from existing North American capacity.
• Genevant Sciences CorporationcoreTechnology or IntegrationLicensed industry-leading lipid nanoparticle intellectual property invented in Canada for use in PTX-COVID19-B vaccine. Genevant provided technical and manufacturing support.
• University of Toronto / Mt. Sinai HospitalminorStrategic or Co-development PartnerAcademic collaborators providing preclinical studies and neutralization assay testing for PTX-COVID19-B development.
• Sunnybrook Research InstituteminorStrategic or Co-development PartnerAcademic collaborator for COVID-19 vaccine research including testing of tri-antigenic mRNA vaccine candidates.
• University of CalgaryminorStrategic or Co-development PartnerAcademic research collaboration partner in Alberta biotechnology ecosystem.
• McMaster UniversityminorStrategic or Co-development PartnerAcademic research collaboration partner.
• PATHminorStrategic or Co-development PartnerGlobal health organization collaborator focused on health innovation.
• Staten Serum InstitutminorStrategic or Co-development PartnerDanish research institute collaborator in vaccine development.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Strand Therapeutics: Preclinical-stage programmable mRNA therapeutics company focused on oncology and immunology. Comparable in therapeutic focus (mRNA + immuno-oncology) but earlier-stage than Providence.

Direct peers

• Arcturus Therapeutics: Clinical-stage mRNA medicines company with a self-amplifying RNA platform, proprietary LNP delivery, and pipeline spanning infectious disease and rare diseases. Directly comparable platform-centric mRNA biotech at similar stage.
• CureVac: Clinical-stage mRNA therapeutics company developing prophylactic vaccines and oncology candidates with proprietary LNP formulations. Closely mirrors Providence's stage, platform structure, and therapeutic-area breadth.
• Gritstone bio: Developer of personalized neoantigen cancer vaccines using mRNA and self-amplifying RNA delivery. The most directly comparable peer in Providence's oncology pipeline (PTX-106, PTX-108) given shared personalized cancer vaccine thesis.

Broad incumbents

• Pfizer: Co-developer of Comirnaty through its partnership with BioNTech and a dominant buyer/licensor of mRNA technologies. Comparable as the benchmark for any mRNA vaccine's clinical and commercial bar.
• BioNTech: Co-developer of Comirnaty — Providence's direct Phase 2 comparator — and a major mRNA immunotherapy player with FixVac and individualized neoantigen cancer vaccine (iNeST) programs. Directly comparable technology base and oncology focus.
• Moderna: The leading commercial mRNA therapeutics company with a broad vaccine and oncology pipeline (including personalized neoantigen programs). Highly comparable to Providence's mRNA + LNP + manufacturing platform, though at vastly greater scale and capitalization.
• Sanofi: Acquired Translate Bio to build an mRNA therapeutics platform across vaccines and rare diseases, and is a frequent comparator for licensing and partnership economics. Comparable as a potential large-pharma partner or acquirer for Providence's platform.

Others

• Alnylam Pharmaceuticals: Leader in nucleic acid therapeutics with established IP and commercialization infrastructure. Adjacent in modality (RNA-based drugs) and shares board-level IP expertise (Donna T. Ward's former employer), making it a relevant comparable for IP-driven nucleic acid biotech.
• Genevant Sciences: Licensor of lipid nanoparticle delivery technology to Providence (and to multiple mRNA developers). Comparable as a direct technology partner and as a benchmark for LNP IP economics in the mRNA ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@PTxHoldingsInc
• LinkedInlinkedin.com/company/providence-therapeutics
• Instagraminstagram.com/providence_therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Providence Therapeutics